Table I.
Clinical information of 19 female breast cancer patients.
| Patient | Response | Age | Subtype | Ki67 (%) | Chemotherapy | |
|---|---|---|---|---|---|---|
| MC-1 | SD/PD | 59 | TNBC | 43 | Paclitaxel → Adriamycin/Cyclophosphamide | |
| MC-2 | PR | 35 | ER−/HER2+ | ND | Paclitaxel + Trastuzumab → Adriamycin/Cyclophosphamide | |
| MC-3 | SD/PD | 60 | Luminal B | 5 | Paclitaxel → Adriamycin/Cyclophosphamide | |
| MC-4 | PR | 48 | TNBC | 6 | Paclitaxel → Adriamycin/Cyclophosphamide | |
| MC-5 | SD/PD | 35 | ER+/HER2+ | 11 | Paclitaxel + Trastuzumab → Adriamycin/Cyclophosphamide | |
| MC-6 | CR | 70 | TNBC | ND | Paclitaxel → Adriamycin/Cyclophosphamide | |
| MC-7 | PR | 38 | TNBC | 75 | Paclitaxel → Adriamycin/Cyclophosphamide | |
| MC-8 | CR | 54 | TNBC | ND | Paclitaxel → Adriamycin/Cyclophosphamide | |
| MC-9 | PR | 53 | TNBC | 6 | Paclitaxel → Adriamycin/Cyclophosphamide | |
| Patient | Response | Age | ER (%) | PgR (%) | HER2 | Chemotherapy |
| TK-1 | SD/PD | 67 | 80 | 0 | 2+ | Epirubicin/Cyclophosphamide → Docetaxel |
| TK-2 | PR | 63 | 20 | 0 | 3+ | Epirubicin/Cyclophosphamide → Docetaxel + Trastuzumab |
| TK-3 | CR | 64 | 0 | 0 | 2+ | Epirubicin/Cyclophosphamide → Paclitaxel + Trastuzumab |
| TK-4 | PR | 56 | 1 | <1 | 2+ | Epirubicin/Cyclophosphamide → Docetaxel |
| TK-5 | PR | 46 | <1 | <1 | 3+ | Epirubicin/Cyclophosphamide → Paclitaxel + Trastuzumab |
| TK-6 | CR | 64 | 0 | 0 | 3+ | Epirubicin/Cyclophosphamide → Paclitaxel + Trastuzumab |
| HG-1 | PR | 48 | 2 | 1 | - | Epirubicin/Cyclophosphamide + Capecitabine → Docetaxel + Capecitabine |
| HG-2 | PR | 57 | 0 | 0 | - | Epirubicin/Cyclophosphamide + Capecitabine → Docetaxel + Capecitabine |
| HG-3 | PR | 71 | 90 | 10 | - | 5-Fluorouracil/Epirubicin/Cyclophosphamide → Docetaxel |
| HG-4 | CR | 40 | 0 | 0 | - | Epirubicin/Cyclophosphamide + Capecitabine → Docetaxel + Capecitabine |
CR, complete response; ER, estrogen receptor; HER2, human epidermal growth factor receptor 2; ND, not done; PgR, progesterone receptor; PR, partial response; SD/PD, stable disease/progressive disease; TNBC, triple-negative breast cancer.